Clinical Trial Update: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the HIV-1 Gag conserved-element DNA vaccine (p24CE) has been completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• HIV-1 Gag Conserved-Element DNA Vaccine (p24CE) (p24CE)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-26